Free tool
FAERS Monitor: Orapred Odt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021959 or its brand name (Orapred Odt, Prednisolone Sodium Phosphate). Reports on generic versions are filed under their own applications.
Reports
2,487
Serious
2,172
87% of reports
Hospitalization
855
Death reported
469
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective215
- off label use196
- pyrexia190
- vomiting183
- condition aggravated170
- pneumonia159
- treatment failure156
- fatigue150
- headache150
- pain149
- asthma144
- hypersensitivity136
- rheumatoid arthritis130
- dyspnoea122
- rash115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 26 |
| 2006 | 77 |
| 2007 | 138 |
| 2008 | 87 |
| 2009 | 15 |
| 2010 | 14 |
| 2011 | 28 |
| 2012 | 28 |
| 2013 | 22 |
| 2014 | 22 |
| 2015 | 26 |
| 2016 | 58 |
| 2017 | 234 |
| 2018 | 424 |
| 2019 | 181 |
| 2020 | 213 |
| 2021 | 83 |
| 2022 | 167 |
| 2023 | 177 |
| 2024 | 138 |
| 2025 | 168 |
| 2026 | 138 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,672 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 156 | 16.0 | 13.7 | 2,176 |
| asthmaSignal | 144 | 10.8 | 9.2 | 1,274 |
| rheumatoid arthritisSignal | 130 | 9.7 | 8.2 | 1,009 |
| hypersensitivitySignal | 136 | 6.2 | 5.3 | 593 |
| condition aggravatedSignal | 170 | 4.7 | 4.1 | 503 |
| pyrexiaSignal | 190 | 4.6 | 4.1 | 549 |
| pneumoniaSignal | 159 | 4.2 | 3.6 | 383 |
| vomitingSignal | 183 | 3.3 | 2.9 | 296 |
| rashSignal | 115 | 2.2 | 1.9 | 79 |
| painSignal | 149 | 2.1 | 1.8 | 82 |
| headacheSignal | 150 | 2.0 | 1.7 | 79 |
| off label use | 196 | 1.9 | 1.7 | 85 |
| dyspnoea | 122 | 1.8 | 1.5 | 46 |
| fatigue | 150 | 1.6 | 1.4 | 37 |
| drug ineffective | 215 | 1.4 | 1.2 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.